Replimune Group (NASDAQ:REPL – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07, Zacks reports.
Replimune Group Trading Down 2.1 %
Replimune Group stock traded down $0.26 during mid-day trading on Wednesday, hitting $11.93. 132,344 shares of the company’s stock were exchanged, compared to its average volume of 1,036,191. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $12.97. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $815.06 million, a P/E ratio of -3.91 and a beta of 1.19. The company’s 50 day simple moving average is $11.42 and its 200-day simple moving average is $9.49.
Insider Buying and Selling at Replimune Group
In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 8.80% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Analysis on REPL
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Stories
- Five stocks we like better than Replimune Group
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Rocket Lab is the Right Stock for the Right Time
- Why Are These Companies Considered Blue Chips?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is the Euro STOXX 50 Index?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.